Partnership to Explore Antibody-Assisted Drug Discovery

摘要

A new research consortium formed by the University of Leicester, MRC Technology and UCB aims to identify opportunities for drug discovery by utilising antibodies in structure-based drug discovery and design. Antibody use will enable identification and characterisation of novel regulatory or allosteric sites on therapeutic target proteins, act to stabilise functionally important protein conformational states, also characterise key structural features of complexes formed with activity modulating antibodies. The knowledge gained by this approach will be exploited to guide the discovery and design of novel small molecule therapeutics, addressing unmet clinical needs and delivering significant benefits for patients.